iShares iBonds 2036年12月期公债ETF IBTR 深 沪
已收盘 07-02 16:00:00 美东时间
24.775
+0.020
+0.08%
华盛通- 最 高24.80
- 今 开24.77
- 成交量 7925股
- 最 低 24.74
- 昨 收 24.755
- 总市值 1114.88万
- 52周最高 25.0096
- 市盈率 静 --
- 换手率 1.76%
- 52周最低 24.2386
- 委 比 0.00%
- 总股本 45.00万
- 历史最高 25.0096
- 量 比 2.62
- 振 幅 0.24%
- 历史最低 24.2386
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuvation Bio to offer $200M convertible senior notes
Nuvation Bio (NUVB) plans to offer $200M aggregate principal amount of convertible senior notes due in 2032 in an underwritten offering. The firm also intends to grant the underwriters a right to purc...
06-25 19:12
Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of
05-27 20:06
Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the
04-22 06:04
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA
The European Medicines Agency has accepted a Marketing Authorisation Application filed by Nuvation Bio (NUVB) and Eisai (ESALF)(ESAIY) for taletrectinib to treat non-small cell lung cancer. The applic...
03-27 05:26
